In recent years, Diapharm has helped over 1,000 medicinal products gain marketing authorisation in Germany and throughout Europe. The Dutch Medicines Evaluation Board (MEB) has always placed an emphasis on the safety and efficacy of medicinal products while demonstrating its openness to innovation, says Dr Bert Verhage, Manager of the Diapharm BV subsidiary in Breda.
Diapharm General Manager Ralf Sibbing also welcomed the EMA’s announcement that it would immediately start planning the relocation process: “I hope that many of the agency’s highly qualified staff will follow the EMA from London to Amsterdam. A smooth relocation will be essential to a consistently high safety and quality of the marketing authorisation and monitoring processes in Europe.”
(approx. 1,450 characters)